Khan S, Rupniewska E, Neighbors M, Singer D, Chiarappa J, Obando C. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019 Aug;44(4):495-507. doi: 10.1111/jcpt.12830
Wadud Z, Chintakayala P. Personal carbon trading: trade-off and complementarity between in-home and transport related emissions reduction. Ecol Econ. 2019 Feb;156:397-408. doi: 10.1016/j.ecolecon.2018.10.016
Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of treatments for advanced non-small cell lung cancer. Am J Pharm Benefits. 2015 Nov;7(6):271-9.
Van Houtven G, Mansfield C, Phaneuf DJ, von Haefen R, Milstead B, Kenney MA, Reckhow KH. Combining expert elicitation and stated-preference methods to value ecosystem services from improved lake water quality. Ecol Econ. 2014 Mar;99:40-52. doi: 10.1016/j.ecolecon.2013.12.018.
Goyal RK, Rajan SS, Essien EJ, Sansgiry SS. Effectiveness of FDA's new over-the-counter acetaminophen label warning requirements in improving consumer risk perception of liver damage. J Clin Pharm Ther. 2012 Dec;37(6):681-5. doi: 10.1111/j.1365-2710.2012.01371.x.
Lopes M, Chulikavit M, Parikh R, Stern L, Liu Z, Rogerio J. Budget impact of everolimus in treating metastatic renal cell carcinoma. Am J Pharm Benefits. 2012;4(Special Issue):sp41-8.
Bristow AL, Wardman M, Zanni AM, Chintakayala PK. Public acceptability of personal carbon trading and carbon tax. Ecol Econ. 2010 Jul 15;69(9):1824-37. doi: 10.1016/j.ecolecon.2010.04.021